Revvity, INC.: management transactions · United States · SEC (Form 4)

About Revvity, INC.

Revvity, Inc. (ticker: RVTY) is a U.S.-based company listed on the NYSE/NASDAQ markets in the United States. It operates in the health science, diagnostics, and life sciences space, with a business model built around enabling workflows from discovery to development, and from diagnosis to cure. The company was launched in 2023 through the rebranding of PerkinElmer, reflecting a sharper strategic focus on higher-value areas such as translational research, biomarker discovery, diagnostics, and scientific software. Revvity’s headquarters are in Waltham, Massachusetts, and the company serves customers in more than 160 countries with roughly 11,000 employees globally. ([ir.revvity.com](https://ir.revvity.com/news/investor-news/news-details/2023/Launching-Revvity-A-Scientific-Solutions-Company-Powering-Innovation-from-Discovery-to-Cure/default.aspx?utm_source=openai)) From an operating standpoint, Revvity is organized around two major pillars: Life Sciences and Diagnostics. Its product and service portfolio includes reagents, consumables, assays, instruments, laboratory services, automation systems, genetic testing, imaging solutions, and software. The company’s Signals software suite is an important differentiator, linking data, workflows, and analytics for biotech, pharma, academia, diagnostic labs, and government customers. Revvity also emphasizes multi-omics, preclinical oncology drug discovery support, viral vector manufacturing, and clinical genetic testing, which broadens the addressable market and makes the business more integrated than a typical single-category tools company. ([revvity.com](https://www.revvity.com/?utm_source=openai)) Revvity’s history matters for investors: it inherits the legacy of PerkinElmer, a long-standing scientific instrumentation and diagnostics business. The 2023 name change was not just cosmetic; it signaled a portfolio shift toward scientific solutions with stronger structural demand and more attractive long-term economics. For international investors, that means Revvity should be viewed as a specialized healthcare technology supplier rather than a traditional pharma company. Its customer base is diversified across pharmaceutical and biotechnology companies, diagnostic laboratories, universities, and public-sector institutions. ([ir.revvity.com](https://ir.revvity.com/news/investor-news/news-details/2023/Launching-Revvity-A-Scientific-Solutions-Company-Powering-Innovation-from-Discovery-to-Cure/default.aspx?utm_source=openai)) Competitive positioning is anchored in breadth and workflow coverage. Revvity can provide tools across the research-to-diagnosis continuum, which creates cross-selling opportunities and supports customer stickiness. The company’s global footprint is also meaningful: it markets products and services in more than 160 countries, with a substantial presence in North America, Europe, and Asia. That geographic diversification reduces dependence on any single end market, although demand remains tied to R&D budgets, clinical testing activity, and spending cycles in life science tools. ([sec.gov](https://www.sec.gov/Archives/edgar/data/31791/000003179125000009/revv-20241229.htm?utm_source=openai)) Recent developments have centered on execution, product innovation, and portfolio optimization. Revvity reported first-quarter 2026 results and continued to highlight its strategic focus on health science solutions. In 2025, management guided full-year revenue in the approximately $2.83 billion to $2.88 billion range in its quarterly communications, while maintaining an organic growth outlook of 2% to 4% in certain periods. That points to a company with moderate top-line growth, supported by recurring consumables and software exposure, but still sensitive to currency movements and the timing of instrument demand. ([ir.revvity.com](https://ir.revvity.com/news/investor-news/news-details/2026/Revvity-Announces-Financial-Results-for-the-First-Quarter-of-2026/default.aspx?utm_source=openai))